Qt prolongation considerations for im hospitalists
This presentation is the property of its rightful owner.
Sponsored Links
1 / 48

QT Prolongation Considerations for IM Hospitalists PowerPoint PPT Presentation


  • 186 Views
  • Uploaded on
  • Presentation posted in: General

QT Prolongation Considerations for IM Hospitalists. Lenny Noronha, MD UNM Hospital Medicine Best Practices 2/8/12. Outline. Review cardiac cycle, pathophysiology Discuss risk factors for Prolonged QT, TdP Analyze medication classes prescribed by Hospitalists

Download Presentation

QT Prolongation Considerations for IM Hospitalists

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Qt prolongation considerations for im hospitalists

QT Prolongation Considerations for IM Hospitalists

Lenny Noronha, MD

UNM Hospital Medicine Best Practices

2/8/12


Outline

Outline

  • Review cardiac cycle, pathophysiology

  • Discuss risk factors for Prolonged QT, TdP

  • Analyze medication classes prescribed by Hospitalists

  • Propose “Best Practices”, discuss


Special thanks to

Special thanks to:

  • Carlos Macias, MD

  • Brook Parrish, MD

  • Davin Quinn, MD

  • Nicole Klein, MD

  • Vincent Zummo, PA

  • KatyaCalvo, MD

  • ShmuelInbar, MD


Qt prolongation considerations for im hospitalists

Case

44yf adm to Red Med team for GI sx, AMS

Adm to Pres 1 wk prior, ureterstented, on cipro 500 po bid.

1. AMS: “MRI pending”. Attributed to K 2.8 and ketones in urine.

2. UTI: Order cultures, start zosyn

3. “Prolonged QTc” Will repeat EKG after electrolytes replaced.

4. Lip lac may need to be sutured.

5. Pain control: tylenol and oxycodone

6. Hospital issues


Case cont d

Case cont’d

Pt seen by neuro before IM eval.

“Feeling funny…my heart fluttering like a butterfly”

QTc 600 documented.

Impression:

  • LOC c tongue abrasion, split lip, most likely secondary to seizure

  • Low potassium

  • Prolonged QT


Qt prolongation considerations for im hospitalists

Initial ED EKG, K 2.8, QTc 602


Qt prolongation considerations for im hospitalists

HD 2, K 3.6, QTc 511


Subsequent course

Subsequent course

HD 2 EEG normal.

Cardiology consult HD 3 after several runs of nonsustained polymorphic VT (8-9 beats).

QTc range 528 – 699 during admission, despite electrolyte replacement

Outpt EKG from 1yr prior: NSR, QTc 467

ID, Pulm consults for complex infection

Started on Bb, titrated to tolerance

Family all had EKG’s. Daughter’s QTc 462.

Pt dc’d c LifeVest, had ICD placed after 14 d course abx, ureteral stone/stent removed


Zoll lifevest wearable defibrillator

ZOLL LifeVest Wearable Defibrillator

http://lifevest.zoll.com/medical-professionals/


What is normal prolonged

What is normal, prolonged?

“Prevention of Torsade de Pointes in Hospital Settings”, Barbara Drew, et al, JACC Scientific statement, 2010; 55, 9:934-947

“The QT interval: Too long, too short or just right”, Sami Viskin, Heart Rhythm, May 2009,: 6, 5: 711-715


Antiarrhythmic overview

Next 9 slides adapted from:

Antiarrhythmic Overview

Carlos Macias, MD

Jan 31st 2012

Fellows Conference


Part 1 basic principals

Part 1. Basic principals

  • Cardiac action potential

    • Electrical impulse of the heart is the summation of thousand of tiny electrical currents generated by thousands of individual cardiac cells.

    • Electrical activity of an individual cardiac cell is described by the cardiac action potential.


Part 1 basic principals1

Part 1. Basic principals

  • Depolarization

    • Phase 0

    • Rapid sodium channels in the cell membrane are stimulated to open.

    • Allows positively charged Na ions to rush into the cell.

    • Voltage spike – positively directed change the transmembrane potential

    • Na channels are voltage dependent.

    • The speed of the slope determined how fast the next cell will be stimulated to depolarize.

    • Anything that causes the causes the slope to change will affect conduction velocity.


Part 1 basic principals2

Part 1. Basic principals

  • Repolarization corresponds to phases 1-3

  • Accounts for most of the action potential

  • Time from the end of phase 0 to late in phase 3 is considered refractory period.

  • Duration of the action potential determines the refractory period.

    • Anything that increases duration of the action potential also changes the refractory period.


Part 1 basic principals3

Part 1. Basic principals

  • Repolarization begins rapidly

    • Phase 1

    • Interrupted by plateau (Phase 2) “slow” Ca channels

    • Most important ionic shift during repol is the outflow of positive K ions.

    • At least six different K “currents” have been identified.

    • At the end of repolarization the transmembrane voltage returns to baseline.


Part 1 basic principals4

Part 1. Basic principals


Part 1 basic principals mechanism of cardiac tachyarrhythmias

Part 1. Basic principalsMechanism of cardiac tachyarrhythmias

Most tachyarrhythmias are thought to be due to one of the following mechanisms:

  • Automaticity

  • Reentry

  • Channelopathy (congenital LQTS)

  • Triggered activity (dig toxarryth, CCB-sens VT, TdP)


Prolonged repol sets up eap

Prolonged Repol sets up EAP

Molecular mechanisms of inherited arrhythmias, Wolf, Berul, et al, Curr Genomics. 2008 May; 9(3): 160–168.


Basic principals triggered mechanism

Basic principalsTriggered mechanism

Ectopy triggered if threshold exceeded


Qt prolongation considerations for im hospitalists

Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes, Gupta, American Heart Journal, Jue 2007; 153: 891-899

Drug-Induced Prolongation of the QT Interval,Dan M. Roden, M.D., N Engl J Med 2004; 350:1013-1022


Notes on tdp

Notes on TdP

  • Usually self-limited

  • Typical symptoms: palpitations, syncope, “seizure-like activity”

  • Immediate tx: Mg Sulfate 2g IV bolus, followed by 2-4g IV infusion over 2 hours


Qt prolongation considerations for im hospitalists

Patient Factors

Direct drug effects

Indirect drug effects

Drugs and the QT Interval — Caveat Doctor

Barbara A. Liu, M.D., and David N. Juurlink, M.D., Ph.D.

N Engl J Med 2004; 351:1053-1056


Patient factors

Patient Factors

  • Female gender

  • Age > 65

  • Electrolyte loss (i.e. Diuretics, Diarrhea)

  • Cardiac disease

  • Liver or Renal disease, Hypothyroidism

  • Congenital LQTS (1:2500 gen population)

    • h/o unexplained syncope, FH sudden death < 40


Direct drug effects most meds that prolong qt thought to block i kr

Direct Drug EffectsMost meds that prolong QT thought to block IKR

Psychiatric

  • Antipsychotics

  • TCA’s

  • Lithium

  • Citalopram

  • Antimicrobials

  • Macrolides

  • Quinolones

  • Azoles

  • Pentamidine

  • Amantadine

  • Other

  • Methadone

  • Hydroxyzine

  • Loratidine

  • Tacrolimus

  • Cocaine

  • Cardiac

  • Quinidine, procainamide

  • Flecainide

  • Amiodarone, Sotalol


Indirect drug effects common c p450 3a4 inhibitors

Indirect Drug EffectsCommonC P450 3A4 Inhibitors

  • Endocrine

  • Ethinylestradiol

  • Gestodene

  • Mifepristone

  • Raloxifene

  • Tamoxifen

Cardiovasc

  • Diltiazem

  • Verapamil

  • Antimicrobials

  • Macrolides!

  • Ketoconazole

  • INH

  • HIV meds

  • Amprenavir, Delavirdine

  • Nelfinavir, Ritonavir

  • Psych

  • Fluoxetine

  • Midazolam

  • Others

  • Grapefruit juice

  • Resveratrol

  • Irinotecan

FYI :This is the mechanism for patients with liver disease


Clinical features associated with risk of tdp

Clinical Features Associated with risk of TdP

“Cardiac side effects of psychiatric drugs” Mackin, Human Psychopharmacology 2008; 23: 3-14.


Literature antibiotics

Literature: Antibiotics


Oral erythromycin and the risk of sudden death from cardiac causes ray nejm 2004

“Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes”, Ray, NEJM 2004

Response to case reports of TdP assoc c IV erythromycin

Retrospective review of TN Medicaid cohort investigated from sudden death ‘88-’93.

Compared matched population “person years” of current and former users of oral erythromycin to patients using amoxicillin at time of investigation


Oral erythromycin and the risk of sudden death from cardiac causes ray nejm 20041

“Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes”, Ray, NEJM 2004

Led to numerous letters, review articles, and…


2006 acc aha esc guideline

2006 ACC/AHA/ESC Guideline

Recommend removing of offending agent in patients with drug-induced LQTS

2010 ACC/AHA Scientific Statement, “Prevention of Torsades de Pointes in Hospital Settings

Recommend continuous cardiac monitoring for drugs at risk to cause TdP. If QTc becomes > 500ms or increases > 60ms, seek alternative therapies, assess for drug interactions. Patients should not be transported from the unit for procedures.


Literature antipsychotics

Literature: Antipsychotics

1980’s: Dose-dependent risk of QTP, TdP, sudden death noted with antipsychotics, especially droperidol, haldol and thioridizine

1990: UK Committee on Safety of Medicines recc gradual dose increase, EKG before and periodically in patients receiving high doses


Literature review cont d

Literature Review cont’d

2007: FDA label warning for QTP/TdP from Haldol IV in response to adverse events reports. Recc: continuous tele monitoring


2010 systematic review meyer massetti

2010 Systematic Review (Meyer-Massetti)

Methods:Cases of QTP/TdP from Pubmed, Embase, Scopus databases (1823-2009; FDA MedWatch reports (‘97-’08)

Results:

70 cases, 2 deaths.

42 of 54 cases of TdP preceded by QTP

68 had identified RF

TdP cases had cumulative dose 5-645 mg

Deaths had cumulative doses of 530, 634 mg


2010 systematic review meyer massetti1

2010 Systematic Review (Meyer-Massetti)

Discussion - APA 2004 recc: Haldol dosing

initial IV dosing 1-2mg q 2-4h

Geriatric: 0.25-0.5mg q4, titrate as needed

Key Conclusion/UCSF policy:

  • IV haldol can be given in cumulative doses

    < 2mg without tele/serial EKG in patients without risk factors

    - Cardiac monitoring if doses greater than 2mg anticipated or risk factors for TdP


Qt prolongation considerations for im hospitalists

Recommendation 1 (Disclosure): Clinicians should inform patients of arrhythmia risk when they prescribe methadone.

Recommendation 2 (Clinical History): Clinicians should ask patients about any history of structural heart disease, arrhythmia, and syncope.

Recommendation 3 (Screening): Obtain a pretreatment electrocardiogram for all patients to measure the QTc interval and a follow-up electrocardiogram within 30 days and annually. Additional electrocardiography is recommended if the methadone dosage exceeds 100 mg/d or if patients have unexplained syncope or seizures.

Recommendation 4 (Risk Stratification): If the QTc interval is greater than 450 ms but less than 500 ms, discuss the potential risks and benefits with patients and monitor them more frequently. If the QTc interval exceeds 500 ms, consider discontinuing or reducing the methadone dose; eliminating contributing factors, such as drugs that promote hypokalemia; or using an alternative therapy.

Recommendation 5 (Drug Interactions): Clinicians should be aware of interactions between methadone and other drugs that possess QT interval–prolonging properties or slow the elimination of methadone.

3/17/09

Especially in doses over 100 mg/d


Suggested best practices

Suggested “Best Practices”

1. Awareness of “Patient Factors” for prolonged QT

  • Age > 65

  • Female

  • ANY cardiac disease

  • Hypokalemia

  • Hypomagnesemia

  • Hypocalcemia

  • CKD, Chronic liver disease, hypothyroidism

  • FH Sudden death/prolonged QT


Suggested best practices1

Suggested “Best Practices”

2. Awareness of chronic outpatient medications most likely to prolong QT interval

- Methadone

- Erythromycin (i.e. gastroparesis)

- Amiodarone

- Atypical antipsychotics

- Tricyclic antidepressants


Suggested best practices2

Suggested “Best Practices”

3. Obtain EKG or tele strip measurement of QTc in patients with Patient Factors/above meds before starting AND after doses of:

  • Antipsychotics

  • Macrolides

  • Quinolones

  • Pentamidine (i.e. PJP)

  • CYP 3A4 inhibitors


Suggested best practices3

Suggested “Best Practices”

Do NOT add meds than can prolong QT in patients with QTc > 500

Discontinue meds that can prolong QT if QTc increases > 60msec after addition


Suggested best practices4

Suggested “Best Practices”

4. Patient Education

www.qtdrugs.org

www.azcert.com


Suggested best practices5

Suggested “Best Practices”

5. Document QTc in progress note if EKG ordered to measure

6. Add diagnosis to Powerchart problem list and Discharge Summary

426.82 – Long QT syndrome (I45.81 in ICD-10)

794.31 – Nonspec Abnormal EKG (R94.31)


Suggested best practices6

Suggested “Best Practices”

For delirious patient with QTc > 500, consider:

  • Trazadone

  • Depakote

  • Seroquel, Abilify (less QT effect)

  • Telephone consultation with PES attending


Questions

Questions?


What is normal qt

What is normal QT?


References

References

“Antiarrhthmic Overview”, Macias, Carlos, Fellow Conference 1/31/12

“Drugs and the QT Interval — Caveat Doctor”, Barbara A. Liu, M.D., and David N. Juurlink, M.D., Ph.D.NEngl J Med 2004; 351:1053-1056

“Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes”, Wayne A. Ray, Ph.D., Katherine T. Murray, M.D., Sarah Meredith, M.B., B.S., SukumarSugunaNarasimhulu, M.B., B.S., M.P.H., Kathi Hall, M.S., and C. Michael Stein, M.B., Ch.B.NEngl J Med 2004; 351:1089-1096

“Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes”, Gupta, American Heart Journal, Jue 2007; 153: 891-899

“Drug-Induced Prolongation of the QT Interval”, Dan M. Roden, M.D., N Engl J Med 2004; 350:1013-1022

“Cardiac side effects of psychiatric drugs” Mackin, Human Psychopharmacology 2008; 23: 3-14.

“Consensus statement on high-dose antipsychotic medication” Royal College of Psychiatrists, October 2005

“Prevention of Torsade de Pointes in Hospital Settings”, Barbara Drew, et al, JACC Scientific statement, 2010; 55, 9:934-947

“The QT interval: Too long, too short or just right”, Sami Viskin, Heart Rhythm, May 2009,: 6, 5: 711-715


  • Login